The North Central Cancer Treatment Group (NCCTG) was founded at a regional group but now has national membership. It is composed predominantly of community clinics that serve the needs of cancer patients within their regions by providing access to new and hopeful clinical research treatment approaches. The NCCTG serves the needs of the National Cancer Program by producing high quality research that will be most relevant to the community practice setting where the overwhelming majority of cancer patients are treated.
The specific aims of the NCCTG over the proposed grant period are the following: 1. To conduct meaningful and scientifically sound clinical cancer research protocols. 2. To set new standards of high quality in the conduct of clinical research trials and in this manner to optimize the validity of results. 3. To foster true multidisciplinary interaction in the planning, execution, and interpretation of clinical cancer research protocols. This interaction will involve medical, surgical and radiation oncologists, pathologists, statisticians, nurses, data handlers, as well as other pertinent medical and surgical subspecialties and laboratory scientists. 4. To evaluate the applicability of new cancer treatment and cancer control approaches at the community level where most cancer patients in this country are managed. 5. To develop the most productive, complimentary and noncompetitive inter-action between community clinics, comprehensive cancer center, and national cooperative groups. 6. To expand our research horizons beyond definitive care of the cancer itself by exploring areas of cancer control including cancer detection and screening, symptomatic management, and nutritional support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA025224-13
Application #
3556741
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-01-01
Project End
1993-12-31
Budget Start
1992-02-19
Budget End
1992-12-31
Support Year
13
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506
Schiff, David; Jaeckle, Kurt A; Anderson, S Keith et al. (2018) Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer 124:1455-1463
McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393
McWilliams, Robert R; Foster, Nathan R; Mahoney, Michelle R et al. (2017) North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 123:3494-3501
Sinicrope, Frank A; Shi, Qian; Allegra, Carmen J et al. (2017) Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol 3:472-480
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703

Showing the most recent 10 out of 718 publications